The Venture Codex

Participated · Equity · Mar 2026

Cedarobo began independent operations in 2025 and focuses on R&D and mass production of embodied intelligent robots. The company has built a core team with experience from RoboSense, XPENG, Tencent AI Lab, DJI, Huawei, and other leading firms, and is led by CEO Cai Youfei, formerly VP of R&D at RoboSense and product director for XPENG's ecosystem, with a CTO who previously led technical work at Tencent AI Lab. Cedarobo says it has developed a multi-functional consumer robot powered by proprietary capabilities including an embodied intelligence large model, high-speed dynamic 3D perception, multimodal semantic analysis, intelligent control algorithms, high-power-density motors, a high-speed chassis, an eagle-eye perception system, and high-precision V-SLAM positioning. The company claims these systems give the robot 360-degree environmental awareness, long-range precision recognition, rapid response, and accurate movement. Financially, Cedarobo closed two rounds in quick succession — a 100 million yuan round in late 2025 and a subsequent round exceeding 100 million yuan — indicating strong investor interest and funding to advance its product and manufacturing plans.

Led · Equity · Jul 2024

Founded in June 2020, Lingchong New Energy focuses on product R&D, manufacturing and sales for electric-vehicle charging/swapping, on-board charging and intelligent testing, as well as intelligent microgrids and energy storage for new power systems. The company operates three production bases in Mianyang (Sichuan), Xixian New Area (Shaanxi) and Haiyan (Zhejiang) and provides full‑scene, full‑lifecycle energy services built on charging networks and smart microgrids. Its charging product range spans 3.5kW–22kW AC units, 20kW–360kW medium/large DC units, and 480kW–960kW superchargers; its storage business targets microgrid scenarios across five subsegments including low‑voltage area management, distributed PV+storage, commercial & industrial storage, integrated PV+storage+charging, and wind/solar+storage microgrids. Lingchong says it has accumulated over 300 domestic patents, about 20 international patent applications, 51 software copyrights, and has led development of more than 10 industry standards. The company positions itself across two hundred‑billion‑yuan‑level new‑energy sectors—charging infrastructure and energy storage—which have been growing quickly in recent years.

Participated · Series B · Apr 2021

EdiGene develops proprietary genome-editing platforms, including ex vivo editing for hematopoietic stem cells and T cells, an in vivo RNA base-editing platform (LEAPER™), and high-throughput genome-editing screening to discover targeted therapies. The company’s lead candidate, ET-01 (a CRISPR/Cas9 therapy for transfusion-dependent β-thalassemia), received the first gene-editing and first hematopoietic stem cell therapy IND approval in China and is preparing for a Phase I trial. EdiGene is also advancing allogeneic CAR-T programs, in vivo RNA base-editing therapies, and other assets discovered via its screening platforms. Founded in 2015, the company is headquartered in Beijing and has offices/operations in Guangzhou, Shanghai and Cambridge, Massachusetts. Financially, EdiGene completed an RMB 400 million (approximately USD 62 million) Series B Plus financing and previously closed an RMB 450 million (approximately USD 67 million) Series B in October 2020. Proceeds from the new round will be used to advance pipeline candidates into the clinic and to scale up business operations, including newly opened clinical, business development, and R&D centers. EdiGene develops genome editing technologies and therapeutics across genetic diseases and oncology. Founded in 2015, the company has established four gene‑editing platforms: ex vivo platforms for hematopoietic stem cells and T cells, an in vivo RNA base‑editing platform, and high‑throughput genome‑editing screening. It opened a GMP manufacturing facility in Guangdong in 2018. EdiGene is advancing its early‑stage programs into clinical development and plans to use new proceeds to move its pipeline into clinics and expand the team. Financially, the company completed a RMB 450 million (approximately USD 67 million) Series B and reported having raised about RMB 700 million (USD 100 million) in the past two years. Headquarters are in Beijing, with subsidiaries in Guangzhou and Cambridge, Massachusetts. EdiGene translates genome‑editing technologies into novel therapeutics for a broad range of diseases and into solutions to advance drug discovery. The company leverages proprietary platforms to develop gene‑editing therapies and to perform high‑throughput genome screening. It has been building an allogeneic CAR‑T platform aimed at off‑the‑shelf T‑cell therapies. EdiGene recently formed a research collaboration with a clinical‑stage biopharmaceutical company to explore new allogeneic T‑cell therapeutic approaches for cancer; the partner and terms were not disclosed. The company completed an approximately $11 Million Series pre‑B2 financing with participation from IDG Capital and Lilly Asia Ventures. EdiGene was founded in 2015 and is headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA. EdiGene develops genome‑editing platforms to create novel therapeutics for genetic diseases and cancer and to enable high‑throughput genome screening for drug discovery. The company leverages proprietary gene‑editing technologies to advance therapeutic candidates toward clinical testing. It recently completed a financing round to support progression of its portfolio and clinic-directed activities. Management has been strengthened with the appointment of Yun Li, MD, as Vice President of Clinical Development to help advance hematology and oncology programs. EdiGene was founded in 2015 and is headquartered in Beijing, with operational subsidiaries in Guangzhou and Cambridge, Massachusetts. The company says the new financing validates and supports its strategy to translate platforms into potential therapeutics. EdiGene develops genome editing technologies into novel therapeutics for genetic diseases and cancer and builds high-throughput genome screening platforms to advance drug discovery. The company leverages proprietary platforms to develop gene-editing therapies and to conduct high-throughput screening that enables dissection of functional big data in biological contexts. EdiGene plans to continue advancing its portfolio of therapeutic programs and to further develop its High Throughput Genome Screening platforms into a comprehensive solution for partners in areas such as drug sensitivity, drug resistance and synthetic lethality. The company completed approximately $15 million in a Series pre-B financing to support these efforts. New investor Huagai Capital participated, along with Series A lead investor IDG Capital, Series A investor WI Harper Group and other insiders. Founded in 2015, EdiGene is headquartered in Beijing with operational subsidiaries in Guangzhou and Cambridge, Massachusetts.

Participated · Equity · Mar 2021

Nice Tuan (also known as Shi Hui Tuan) is a Chinese e-grocery platform that lets shoppers form groups through a WeChat mini-program to collectively buy farm produce and other groceries in bulk at competitive prices. The Beijing-based app leverages community group-buying to drive lower prices and volume sales. The company raised $750 million in a financing round co-led by Alibaba and DST Global. Last year it secured nearly $450 million across four funding rounds, including a $196 million “Series C3” in December co-led by Alibaba and Jeneration Capital. Nice Tuan operates in a highly competitive segment as other group-buying and fresh-produce e-grocers—such as Tongcheng Life and MissFresh—attract investment from major tech firms. Cygnus Equity’s managing director praised Nice Tuan’s management, strategic vision and execution, saying those qualities position the company to win in the evolving community group-buying market. Nice Tuan is a two-year-old China-based community group-buying startup that organizes neighborhood grocery orders via WeChat group chats. It relies on neighborhood managers—often part‑time local residents—to promote products, tally orders, place bulk orders with suppliers, and arrange community pick-up at local convenience stores. The model emphasizes self-pickup at community pick-up spots rather than doorstep delivery, which can make ordering more accessible for elderly shoppers and enable bulk discounts. The company has attracted major investment: Alibaba co-led a $196 million C3 funding round, and this was Nice Tuan's fourth round so far this year. The firm could expand its offering by adding last-mile delivery and competes with Tencent-backed Xingsheng Youxuan, Meituan, Pinduoduo and Alibaba’s Hema. Nice Tuan (also known as Shi Hui Tuan) operates a community e-grocery platform that lets users band together to bulk-purchase fresh produce—often via an agent—to lower prices and improve vendor economics. The platform also sells non-perishable foods, snacks, health and beauty products, and everyday household items, and promises same-day or next-day delivery for most fresh purchases. Launched in 2018 and based in Beijing, Nice Tuan says it serves around 20 million urban households across 100 cities and was designated an essential service by several provincial and municipal governments during China’s Covid-19 lockdown. The company will use the new funds to enhance warehousing and distribution capacity and strengthen its supply chain. Over the next three years it plans to create about 3 million self pick-up points across China to bring most users within a five-minute walk of collection points. To date the startup has raised nearly $300 million, with a large portion of that capital raised since the start of the year.

Participated · Series B · Jan 2021

Dianxiaomi builds ERP and seller tools for Chinese cross-border e-commerce vendors, starting from a one-click Taobao-to-Wish listing tool and expanding into a full enterprise suite. The company targets small and medium-sized sellers handling up to 5,000 orders per day. It says it serves 1.5 million users globally, including 430,000 users in Southeast Asia, and has partnered with about 50 e-commerce platforms. Dianxiaomi has launched localized ERP products for sellers in Southeast Asia and Latin America and is expanding overseas. The company plans to open offices in Indonesia, Malaysia and the U.K., with teams of 20–100 staff in each country for customer service and operations. Financially, Dianxiaomi announced a $110 million Series D and said total investment reached $210 million in 2022 alone. Founder and CEO Du Jianyin, a former Baidu R&D engineer, leads the company. Dianxiaomi (Shenzhen Meiyunji Network Technology Co., Ltd.), founded in 2014, provides SaaS ERP systems and e-commerce enabling services for global sellers. Its product suite covers cross-border eCommerce solutions, customer service, logistics tracking, shared warehousing, and BigSeller (founded in 2019) for order aggregation, product listing, data analytics, and inventory management across marketplaces. Products are available in English, Bahasa, Vietnamese, and Thai, and the company has a team in Indonesia with plans to expand further in Southeast Asia. Headquartered in China, Dianxiaomi reports more than 1.2 million global users, partnerships with over 50 e-commerce platforms, 800+ logistics providers, and more than 60 overseas warehouses. The company processes annual order transaction amounts exceeding 3,000 billion RMB. It plans to use the new funding for product development, talent acquisition, service upgrades, and global expansion of its e-commerce enabler. Dianxiaomi builds ERP tools that help SMEs operate overseas e-commerce businesses across 32 platforms, including Amazon, eBay, Shopify and AliExpress. The company is Shenzhen-based and was set up in 2014. It claims to have approximately 70,000 users. Dianxiaomi focuses on product capabilities that streamline cross-border listings, order management and channel integration. The company recently closed a 150 million yuan Series B, which it says will fund product innovation, market expansion and recruitment. The raise positions Dianxiaomi to scale its platform and expand its presence in international e-commerce markets.